Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Tables)

NON CONTROLLING INTEREST (Tables)

9 Months Ended

Sep. 30, 2024

NON CONTROLLING INTEREST

Schedule of net loss attributable to non-controlling interest

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(106,233	)		$	244
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(25,708	)		$	85

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(2,397	)		$	(1,395	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(580	)		$	(488	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(175,033	)		$	(1,720	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(42,358	)		$	(602	)

		BioCorRx Pharmaceuticals, Inc.				Joseph DeSanto MD
Net loss		$	(5,692	)		$	(4,945	)
Average Non-controlling interest percentage of profit/losses			24.2	%			35.0	%
Net loss attributable to the non-controlling interest		$	(1,378	)		$	(1,730	)

Schedule of changes in non controlling interest

Balance, December 31, 2023		$	(128,834	)
Net loss attributable to the non-controlling interest			(42,960	)
Balance, September 30, 2024			(171,794	)

Balance, December 31, 2022		$	(125,257	)
Net loss attributable to the non-controlling interest			(3,108	)
Balance, September 30, 2023			(128,365	)